| Document |
Document Title |
|
WO/2010/111460A1 |
The invention relates to compounds of formulae (1) and (2), and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular dis...
|
|
WO/2010/108584A1 |
The present invention relates to a process for preparing N-substituted furan-2(5H)-ones where the reaction medium comprises at least one Ionic Liquid, to the use of Ionic Liquids for preparing furan-2(5H)-ones, and to compounds preparabl...
|
|
WO/2010/110647A1 |
The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with an estrogen receptor (ER) related disease or condition of the animal or human bod...
|
|
WO/2010/111437A1 |
This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for pre...
|
|
WO/2010/106290A1 |
The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R'1 radicals selected from H, halogen, CF3, ni...
|
|
WO/2010/107085A1 |
Provided is a novel alicyclic epoxy resin which provides a cured material having excellent heat resistance, optical properties, and toughness. The epoxy resin comprises a diolefin compound represented by formula (1) as a starting materia...
|
|
WO/2010/104194A1 |
The present invention provides a compound represented by the following formula (I): wherein: Ring A represents an optionally substituted piperazine ring, an optionally substituted morpholine ring, or an optionally substituted bomopiperaz...
|
|
WO/2010/101973A1 |
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, JV-oxides, and salts thereof, wherein Q1 is a phenyl ring, naphthalenyl ring system, a 5- to 6-membered fully unsaturated heterocyclic ring or an 8- to 10...
|
|
WO/2010/101839A2 |
Chemiluminescent compositions, methods, assays and kits for oxidative enzymes are described. Further disclosed are dioxetane compounds of the form: 0-0 ΛR R R T (i) where R can independently be any branched alkyl or cycloalkyl group whi...
|
|
WO/2010/092289A1 |
The invention relates to 3-benzofuranyl-indol-2-one derivatives substituted at the 3 position and of the formula (I) where R1, R2, R3, R4, R5 and n are such as defined in claim 1, to a method for preparing same, and to the therapeutic us...
|
|
WO/2010/092288A1 |
The invention relates to disubstituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives of the general formula (I) where R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are such as defined in claim 1, to a method for preparing same,...
|
|
WO/2010/086366A1 |
The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; m free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
|
|
WO/2010/081755A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2010/080537A1 |
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
|
|
WO/2010/077992A1 |
Pyridine and pyrimidine compounds: (I); or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; (II); or a pharmaceutically accep...
|
|
WO/2010/076879A1 |
Provided are a sulfated C-glycoside which is a novel compound serving as a precursor of chafuroside and chafuroside analogs; a method for efficiently producing the sulfated C-glycoside; and a method for efficiently producing chafuroside ...
|
|
WO/2010/077976A2 |
Contemplated compounds, compositions, and methods of prokineticin antagonists are presented where a prokineticin antagonist is used in the treatment and prevention of various conditions and disorders, and especially type II diabetes.
|
|
WO/2010/073235A1 |
Method for treating or preventing a PPAR-responsive condition in a subject, comprising administering to the subject a PPAR agonist that comprises a 8-hydroxyquinoline-methylene-N- group in an amount effective to activate a PPAR polypeptide.
|
|
WO/2010/075270A1 |
The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as thei...
|
|
WO/2010/072770A2 |
The invention relates to compounds of the formula (I), where the symbols have the meaning given in the specification, for use in a method for treating cancer, to use of these compounds for the manufacture of a pharmaceutical composition ...
|
|
WO/2010/069877A1 |
The present invention relates to isothiazole and pyrazole compounds of formula (I) having plant growth regulating properties, to agricultural compositions comprising them, and to the use of said compounds for regulating plant growth.
|
|
WO/2010/070032A1 |
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein ...
|
|
WO/2010/067036A1 |
The present invention relates to novel compounds of formula (I) where: X is an –OH or =O grouping; n is an integer between 0 and 5; R’ is H or a C1-C4 alkyl radical, when n ≥ 2, two adjacent –OR’ groupings can together form the...
|
|
WO/2010/068720A2 |
The present invention relates to new podophyllotoxin inhibitors of topoisomerase II, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2010/068663A1 |
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of pr...
|
|
WO/2010/067067A1 |
Compounds of general formula (I): wherein R1, R2, R3, R4, R5, R6, X and Y are as defined herein are inhibitors of Bcl-2 and are useful for treating diseases characterised by abnormal cell growth and/or dysregulated apoptosis.
|
|
WO/2010/064735A1 |
The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as t...
|
|
WO/2010/060379A1 |
Ether compounds with nitrogen-containing 5-member heterocycle, shown as formula (I), in which the definitions of substituents are shown in description. The compounds of present application have broad-spectrum insecticidal activities, and...
|
|
WO/2010/062265A1 |
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as "MC compounds"), which, inter alia, are useful in t...
|
|
WO/2010/060955A1 |
The present application discloses novel 2-morpholino-3-amido-pyhcline derivatives and their use as modulators of the voltage gated KV7 (KCNQ) potassium ion channels in the treatment of pain, neurodegenerative disorders, urinary incontine...
|
|
WO/2010/059393A1 |
The biphenyic compounds of formula (I) are serotonin modulators useful in the treatment of serotonin-mediated diseases.
|
|
WO/2010/059611A2 |
The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase ("DGAT") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventin...
|
|
WO/2010/056585A2 |
Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I).
|
|
WO/2010/055267A1 |
Compound corresponding to general formula (I): in which R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6- alkoxy or NR8R9 group; n is an integer equal to 1, 2 or 3 and m is an integer equal to 1 o...
|
|
WO/2010/056320A2 |
6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine and 2-morpholin-4-yl-7H- pyrrolo[2,3-d]pyrimidine derivatives have unexpected drug properties as inhibitors of PI3 and/or mTOR kinases and are useful in treating disorders related to abnormal PI...
|
|
WO/2010/057121A1 |
Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent...
|
|
WO/2010/053182A1 |
A kynurenine production inhibitor or the like, which contains a nitrogen-containing heterocyclic compound represented by formula (I). (In the formula, R50 and R51 may be the same or different and each represents a hydrogen atom or the l...
|
|
WO/2010/050445A1 |
A compound having an ACC inhibitory effect and useful for prevention/treatment of adiposis, diabetes, hypertension, hyperlipemia, heart failure, diabetic complication, metabolic syndrome, sarcopenia, cancer and the like. The compound ha...
|
|
WO/2010/051277A1 |
The invention discloses novel processes for production, enrichment and/or isolation of alpha-tocotrienol from source material comprising at least one non-alpha-tocotrienol, such as natural extracts comprising mixed tocotrienols.
|
|
WO/2010/042477A1 |
In its many embodiments, the present invention provides a novel class of benzodioxan analogues as modulators of the α2C adrenergic receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more such co...
|
|
WO/2010/040843A2 |
The invention relates to compounds of formula (I), in which R1, R2, R3, R4, X and Y are defined as cited in the description. The compounds have an immune-modulating action and inhibit or regulate the release of IL-1β and/or TNF-α. They...
|
|
WO/2010/041670A1 |
A novel alicyclic epoxy resin having no ester bond in each molecule, and a precursor of the alicyclic epoxy resin. The precursor is a diolefin compound represented by formula (1) (wherein each of the plurality of R's independently repres...
|
|
WO/2010/039256A1 |
A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or ...
|
|
WO/2010/037210A1 |
The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical compositions co...
|
|
WO/2010/034657A1 |
This invention relates to novel indazole derivatives of formula (I), wherein R1 to R7 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be...
|
|
WO/2010/034927A1 |
The invention relates to a method for preparing nebivolol, and more particularly to an improved method for the synthesis of an alpha-haloketone of the formula (I), which is a key intermediate in the preparation of nebivolol.
|
|
WO/2010/031852A1 |
The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provid...
|
|
WO/2009/124723A9 |
This invention relates to the field of biologically active compounds and specifically to novel aureothin derivatives, pharmaceutical compositions comprising these novel aureothin derivatives, methods for the production of the aureothin d...
|
|
WO/2010/030727A1 |
The invention relates to 3-substituted-1H-indole, 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein the constituent v...
|
|
WO/2010/028655A1 |
The invention relates to isoquinolinone derivatives useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said comp...
|
